Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taher Al-Tweigeri

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Neoplasia (New York, N.Y.)|April 14, 2006
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factorsHazem Ghebeh, Shamayel Mohammed, Abeer Al-Omair, et al.
Breast Care (Basel, Switzerland)|March 15, 2021
Trastuzumab, Pertuzumab, and Docetaxel as the First Line for HER-2-Positive Metastatic Breast Cancer among ArabsKausar Suleman, Ali Hassan Mushtaq, Emaan Haque, et al.
Plos One|May 25, 2013
Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young womenDilek Colak, Asmaa Nofal, Albandary Albakheet, et al.
Oncology and Therapy|November 19, 2025
Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi ArabiaSabah Alaklabi, Sadal Al Refaei, Omalkhair Abualkhair, et al.
The New England Journal of Medicine|June 3, 2005
Adjuvant docetaxel for node-positive breast cancerMiguel Martin, Tadeusz Pienkowski, John Mackey, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Neoplasia (New York, N.Y.)|April 14, 2006
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factorsHazem Ghebeh, Shamayel Mohammed, Abeer Al-Omair, et al.
Breast Care (Basel, Switzerland)|March 15, 2021
Trastuzumab, Pertuzumab, and Docetaxel as the First Line for HER-2-Positive Metastatic Breast Cancer among ArabsKausar Suleman, Ali Hassan Mushtaq, Emaan Haque, et al.
Plos One|May 25, 2013
Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young womenDilek Colak, Asmaa Nofal, Albandary Albakheet, et al.
Oncology and Therapy|November 19, 2025
Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi ArabiaSabah Alaklabi, Sadal Al Refaei, Omalkhair Abualkhair, et al.
The New England Journal of Medicine|June 3, 2005
Adjuvant docetaxel for node-positive breast cancerMiguel Martin, Tadeusz Pienkowski, John Mackey, et al.
Pageof 5